Gene Fusions in Cancer

What a fusion means, how testing finds it and why the method matters

Key takeaways

• A fusion joins material from different genes; it is not simply two separate mutations.
• Some fusions matter for cancer diagnosis or treatment, while others need further interpretation.
• DNA, RNA, FISH, PCR and IHC do not all measure the same thing.
• Detection depends on assay design, target coverage and specimen quality.
• A fusion result needs the exact event and tumor context, not just a gene name.

How a gene fusion can arise

A gene fusion can form when parts of different genes become joined. Some fusions contribute to cancer biology and may have clinical significance, but the exact event, assay and tumor context determine how a result is interpreted.

Parts of chromosomes can rearrange, bringing gene segments together in a new configuration. This can create a joined gene or transcript and, in some cases, an altered protein. Not every rearrangement has the same effect, and not every detected fusion is an established cancer driver.^[1]

Fusion notation often names two partner genes. The order and detailed structure can matter to laboratory interpretation. A patient does not need to reconstruct the sequence to discuss the result, but it is important to keep the complete report wording rather than reducing it to one familiar gene name.

Oncquest's specialised diagnostics services include gene sequencing, molecular biology, cytogenetics and IHC. That range is relevant to fusion investigations because different methods can examine different features of an event. The appropriate Oncquest order depends on the suspected finding and tumor context, rather than assuming every sequencing panel detects every fusion.^[10]

Method	What it can contribute
DNA sequencing	Looks for rearrangements within the regions and event types covered by the assay.
RNA sequencing	Can identify expressed fusion transcripts within its validated design.
Targeted PCR	Can investigate specified transcript targets; coverage depends on assay design.
FISH	Uses probes to assess selected rearrangements; may not identify the full fusion partner.
IHC	Assesses protein expression and may support selected testing pathways; it is not direct sequencing of a fusion.

Why some fusions matter in cancer

Certain fusions can influence the signals that control cell growth. In some cancer settings, a recognised fusion may support a diagnosis, contribute prognostic information or identify a treatment-related biomarker. Examples in lung-cancer pathways include relevant ALK, ROS1 and RET fusions; NTRK fusions can be relevant across selected tumor types.^[3][4]

These are clinical examples, not proof that every fusion involving those genes has the same meaning. The exact event, cancer type and strength of evidence remain important. A fusion-associated treatment also has clinical and regulatory conditions that cannot be reduced to the presence of a name in a report.

What DNA-based testing can find

A DNA-based assay looks for rearrangement evidence within genomic regions it is designed to analyse. Its ability to detect a particular event depends on which regions are covered and the technical approach used. A panel can cover sequence variants in a gene without providing equally comprehensive fusion detection for that gene.

This is why a gene list alone is insufficient. Ask whether rearrangements or fusions are validated outputs and whether the clinically relevant events fall within the test's design. A negative DNA result may leave a fusion question open when the relevant regions or event types were not adequately assessed. The next method should be chosen to address that specific gap.^[2]

What RNA-based testing adds

RNA analysis can detect an expressed joined transcript. It can therefore provide complementary evidence about a fusion event, provided the transcript is covered by the assay and the sample contains usable RNA. RNA testing is not automatically unrestricted: some designs target specified partners or junctions, while others can investigate a wider range.

Research in the NCI-MATCH screening cohort illustrates that different fusion-detection approaches can identify different sets of events. It should not be used to promise a detection rate for an unrelated commercial assay. The relevant lesson is to understand assay design and limitations, not to assume that any test labelled RNA will find every possible fusion.^[2]

Where FISH, PCR and IHC fit

Other methods can be useful in defined diagnostic pathways. FISH uses probes to assess selected rearrangements. Targeted PCR can examine specified transcript targets. IHC detects protein expression and may be used in selected screening or diagnostic algorithms. None should be described as universally interchangeable with DNA or RNA sequencing.

The testing pathway depends on the tumor and the question. A screening result may require a different form of confirmation in some settings, while a validated diagnostic approach may be sufficient in others. Ask the pathologist which method was used and whether any additional assessment is needed for the intended clinical decision. Avoid ordering repeated tests without knowing what uncertainty remains.

Reading a fusion result

Look for partner-gene names, relevant transcript or breakpoint information, the method used and the laboratory's interpretation. Some reports include supporting-read information or other quality measures. A result may be classified by clinical evidence or accompanied by a statement that its significance is uncertain.

Oncquest's CGP sample reports show methodology and fusion-related reporting elements. When reading your own report, distinguish a detected event from an established therapeutic target and from a possible trial association. If the wording is unclear, ask the laboratory for clarification rather than trying to infer the biological effect from the name alone.^[5][6]

Do not confuse fusions with other alterations

A point mutation changes a DNA letter. A copy-number alteration changes how many copies of a region are present. A splice alteration affects how an RNA transcript is assembled. A fusion joins material from different genes. These categories can all appear in genomic reports, but they are not synonyms.

For example, MET exon 14 skipping is a splicing event rather than simply a fusion between two genes. Likewise, an NTRK mutation or amplification should not automatically be read as an NTRK fusion. The exact alteration class is part of the clinical evidence needed to interpret a finding.^[3][4]

Discussing fusion testing with Oncquest

Verified Oncquest offering facts

1

CGP 270+ fusion scope

Oncquest's OncqSol CGP 270+ (SMO10765) includes fusions in its catalogue scope.

2

DNA and RNA methodology

The sample reports for CGP 270+ and CGP 550+ (OMO1034) describe DNA and RNA analysis and fusion-related methodology.

Why it matters for you

For either product, use the current technical specification to confirm the relevant targets and event types; the short catalogue component list does not describe every methodological detail.

For a fusion-specific enquiry, contact Oncquest at 0124 6650000 or life@oncquestlabs.com with the prescribed test code and the fusion question raised by the treating team. Ask about target and partner coverage, RNA requirements and limitations for the available tissue. If an earlier result was negative, explain what remains unresolved so the clinician can assess whether another method would add useful information.^[11]

Limits and the next clinical discussion

A negative result can reflect true absence, incomplete target coverage, low tumor content, degraded RNA or another technical limitation. An uncertain finding may need specialist review. The report should be considered alongside pathology and the original reason for testing, rather than interpreted as an isolated molecular label.

• Was the relevant fusion question adequately assessed?
• Is the reported event established, uncertain or in need of confirmation?
• Does it affect diagnosis, prognosis, treatment or trial assessment in this cancer?
• Are the cited options current and accessible in this clinical setting?
• Does any aspect of the result warrant separate inherited-risk assessment?

Most tumor findings cannot establish family risk by themselves. Germline questions require their own clinical assessment and, where appropriate, confirmation.^[9]

Frequently asked questions

FAQs

Is a fusion just two mutations together?

No. It involves joined material from different genes. Two independent sequence variants are not automatically a fusion.

Does every gene fusion cause cancer?

No. Some are established drivers or diagnostic markers; others are uncertain or have no established clinical role. The exact event and context matter.

Can DNA testing miss a fusion?

It can if the relevant event lies outside the validated coverage or is difficult to detect with that assay. RNA or another method may be considered when it addresses a meaningful unresolved question.

Is RNA testing always better?

No single method is best for every question. RNA quality, assay design and target coverage matter, and different methods can provide complementary information.

Does an NTRK mutation mean an NTRK fusion?

No. Sequence mutations, amplifications and fusions are different alteration classes. Treatment evidence must match the actual finding.

Does a detected fusion mean relatives need testing?

Not automatically. A tumor result alone does not establish inherited risk. Discuss any separate genetic-counselling question with the clinical team.

Sources

1. National Cancer Institute — Fusion Gene Definition and biological context.
2. NCI-MATCH — Discovery of Gene Fusions in Driver-Negative Samples Primary research illustrating assay-design differences in fusion detection; not a product performance claim.
3. National Cancer Institute — Non-Small Cell Lung Cancer Treatment (PDQ) Disease-specific biomarker and treatment context; examples are not an assay coverage list.
4. National Cancer Institute — Agnostic Cancer Therapies (PDQ) Clinical evidence and explicitly US regulatory context; not an Indian prescribing rule.
5. Oncquest — CGP 270+ Sample Report Supplied SMO10765 example reviewed for structure and methodology only; individual findings are not reproduced.
6. Oncquest — CGP 550+ Sample Report Supplied OMO1034 example reviewed for structure and methodology only; individual findings are not reproduced.
7. Oncquest — OncqSol CGP 270+ Official catalogue: test code, specimen and listed scope.
8. Oncquest — OncqSol CGP 550+ Official catalogue: test code, specimen and listed biomarkers.
9. National Cancer Institute — Genetic Testing Fact Sheet Inherited-risk testing, consent and genetic counselling.
10. Oncquest — Company Overview Oncology focus, specialised diagnostic disciplines and laboratory network.
11. Oncquest — Patient Services and Enquiries Test search, centre search, online report access and published enquiry contacts.